
Brontictuzumab
CAS No. 1447814-75-6
Brontictuzumab ( —— )
产品货号. M36719 CAS No. 1447814-75-6
Brontictuzumab (OMP 52M51) 是一种单克隆抗体 (MAb),可抑制 Notch1 信号。Brontictuzumab 选择性结合 Notch1 的负调控区域。Brontictuzumab 可抑制肿瘤细胞增殖。Brontictuzumab 可用于白血病和淋巴瘤的研究。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
2MG | ¥3837 | 有现货 |
![]() ![]() |
5MG | ¥6258 | 有现货 |
![]() ![]() |
10MG | ¥9932 | 有现货 |
![]() ![]() |
25MG | ¥14311 | 有现货 |
![]() ![]() |
50MG | ¥19394 | 有现货 |
![]() ![]() |
100MG | ¥25475 | 有现货 |
![]() ![]() |
500MG | 获取报价 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称Brontictuzumab
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述Brontictuzumab (OMP 52M51) 是一种单克隆抗体 (MAb),可抑制 Notch1 信号。Brontictuzumab 选择性结合 Notch1 的负调控区域。Brontictuzumab 可抑制肿瘤细胞增殖。Brontictuzumab 可用于白血病和淋巴瘤的研究。
-
产品描述Brontictuzumab (OMP 52M51) is a monoclonal antibody (MAb) that inhibits Notch1 signal. Brontictuzumab selectively binds the negative regulatory region of the Notch1. Brontictuzumab inhibits tumor cell proliferation. Brontictuzumab can be used in the research of leukemia and lymphoma.
-
体外实验Brontictuzumab (0-100 μg/mL) inhibits Notch1 signaling, including DLL4, JAG1/2 activity.Brontictuzumab (25 μg/mL, 4 days) reduces the levels of Notch1 intracellular domain in the HPB-ALL cell line.Brontictuzumab (25 μg/mL, 48 h) inhibits DLL4-mediated cleaved-Notch1 overexpression in MCL cells.Brontictuzumab (25 μg/mL, 48 h) blocks the increased phosphorylation of both, MEK and ERK by DLL4 stimulation in Mino cells..Western Blot Analysis Cell Line:DLL4 (4?μg/mL)-stimulated MCL cells Concentration: 25 μg/mL Incubation Time:24 or 48 h Result:Inhibited DLL4-dependent activation of Notch1.
-
体内实验Brontictuzumab (15 mg/kg, i.p.) reduces tumor burden in T-ALL xenograft.Brontictuzumab (20 mg/kg, i.p., every 4?days) inhibits DLL4 induced activation of Notch1 in MCL model.Animal Model:T-ALL xenograftDosage:15 mg/kg Administration: Intraperitoneal injection (i.p.), twice weekly.Result:Inhibited tumor growth and reduced the size of the spleen.Showed massive infiltration and replacement of normal hematopoiesis by leukemia cells.Animal Model:NSG mice injected with DLL4-stimulated NOTCH1-mutated mino cells ex vivo Dosage:20 mg/kg Administration:Intraperitoneal injection (i.p.)Result:Inhibited cleaved Notch1 but was not enough to cause a significant efficacy in tumor growth.
-
同义词——
-
通路Neuroscience
-
靶点Gamma-secretase
-
受体Gamma-secretase
-
研究领域——
-
适应症——
化学信息
-
CAS Number1447814-75-6
-
分子量
-
分子式——
-
纯度>98% (HPLC)
-
溶解度——
-
SMILES——
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Ferrarotto R, et al. A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors. Ann Oncol. 2018 Jul 1;29(7):1561-1568. ?
产品手册




关联产品
-
CIA-1 (Free base)
CIA-1 (Free base) is a nuclear receptor COUP-TFII inhibitor with IC50 values ranging from 1.2 μM to 7.6 μM in prostate cancer cell lines. CIA-1 (Free base) inhibits tumor growth in a mouse model of prostate cancer xenografts.
-
γ-Secretase modulato...
γ-Secretase modulator 13 (compound 4) 是一种 γ-分泌酶调节剂 (GSMs),可以抑制聚集的淀粉样蛋白 β 肽Aβ42 的产生,其 IC50 值为163 nM。可以用于阿尔茨海默病的研究。
-
MRK-560
MRK-560 是一种有效的脑渗透性 γ-分泌酶抑制剂。